Sreeram V Ramagopalan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4677471/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Increasing cancer risk over calendar year in people with multiple sclerosis: a case–control study. Journal of Neurology, 2021, 268, 817-824.	1.8	6
2	Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer. Journal of Comparative Effectiveness Research, 2021, 10, 595-602.	0.6	4
3	Effect of Vitamin D supplements on relapse rate and Expanded Disability Status Scale (EDSS) in multiple sclerosis (MS): A systematic review and meta-analysis. International Journal of Preventive Medicine, 2021, 12, 42.	0.2	13
4	R WE ready for reimbursement? A round up of developments in real-world evidence relating to HTA: part 3. Journal of Comparative Effectiveness Research, 2021, 10, 1175-1176.	0.6	0
5	Life after COVID-19: R WE going to help?. Journal of Comparative Effectiveness Research, 2020, 9, 525-526.	0.6	3
6	Commonly used definitions in real-world studies may underestimate the prevalence of renal disease among nonvalvular atrial fibrillation patients. Journal of Comparative Effectiveness Research, 2019, 8, 961-968.	0.6	0
7	Validity of social media for assessing treatment patterns in oncology patients: a case study in melanoma. JAMIA Open, 2019, 2, 416-422.	1.0	5
8	Real-world data and the patient perspective: the PROmise of social media?. BMC Medicine, 2019, 17, 11.	2.3	44
9	Discontinuation and primary care visits in nonvalvular atrial fibrillation patients treated with apixaban or warfarin. Journal of Comparative Effectiveness Research, 2019, 8, 371-379.	0.6	6
10	Age at menarche and risk of multiple sclerosis (MS): a systematic review and meta-analysis. BMC Neurology, 2019, 19, 286.	0.8	7
11	The Effect of Vitamin D Supplements on Clinical and Para-Clinical Outcomes in Patients With Multiple Sclerosis: Protocol for a Systematic Review. JMIR Research Protocols, 2019, 8, e12045.	0.5	11
12	Performing studies using the UK Clinical Practice Research Datalink: to link or not to link?. European Journal of Epidemiology, 2018, 33, 601-605.	2.5	18
13	Sleep and BMI: Do (Fitbit) bands aid?. F1000Research, 2018, 7, 511.	0.8	5
14	Under-recording of hospital bleeding events in UK primary care: a linked Clinical Practice Research Datalink and Hospital Episode Statistics study. Clinical Epidemiology, 2018, Volume 10, 1155-1168.	1.5	8
15	Prodromal symptoms of multiple sclerosis in primary care. Annals of Neurology, 2018, 83, 1162-1173.	2.8	98
16	Sleep and BMI: Do (Fitbit) bands aid?. F1000Research, 2018, 7, 511.	0.8	5
17	Time to really share real-world data?. F1000Research, 2018, 7, 1054.	0.8	12
18	Real-world data really matter. Cmaj, 2017, 189, E1293-E1293.	0.9	2

#	Article	IF	CITATIONS
19	Lack of data sharing in observational studies. BMJ: British Medical Journal, 2017, 359, j4866.	2.4	7
20	An analysis of characteristics of post-authorisation studies registered on the ENCePP EU PAS Register. F1000Research, 2017, 6, 1447.	0.8	13
21	An analysis of characteristics of post-authorisation studies registered on the ENCePP EU PAS Register. F1000Research, 2017, 6, 1447.	0.8	11
22	A review of data sharing statements in observational studies published in the BMJ: A cross-sectional study. F1000Research, 2017, 6, 1708.	0.8	10
23	A review of data sharing statements in observational studies published in the BMJ: A cross-sectional study. F1000Research, 2017, 6, 1708.	0.8	8
24	Unintended consequences of machine learning in medicine?. F1000Research, 2017, 6, 1707.	0.8	15
25	A Risk Score for Predicting Multiple Sclerosis. PLoS ONE, 2016, 11, e0164992.	1.1	11
26	Real-world data in the United Kingdom: opportunities and challenges. BMC Medicine, 2016, 14, 97.	2.3	30
27	Serostatus of Epstein–Barr virus in Iranian MS patients. Acta Neurologica Belgica, 2016, 116, 43-46.	0.5	2
28	The senescent methylome and its relationship with cancer, ageing and germline genetic variation in humans. Genome Biology, 2015, 16, 194.	3.8	40
29	Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies. BMC Neurology, 2015, 15, 16.	0.8	31
30	Funding source and primary outcome changes in clinical trials registered on ClinicalTrials.gov are associated with the reporting of a statistically significant primary outcome: a cross-sectional study. F1000Research, 2015, 4, 80.	0.8	17
31	Funding source and primary outcome changes in clinical trials registered on ClinicalTrials.gov are associated with the reporting of a statistically significant primary outcome: a cross-sectional study. F1000Research, 2015, 4, 80.	0.8	15
32	Evidence for an Association Between Vitamin D and Multiple Sclerosis. Current Topics in Behavioral Neurosciences, 2014, 26, 105-115.	0.8	17
33	Regulatory genomic regions active in immune cell types explain a large proportion of the genetic risk of multiple sclerosis. Journal of Human Genetics, 2014, 59, 211-215.	1.1	6
34	Multiple sclerosis in Isfahan, Iran: an update. Multiple Sclerosis Journal, 2014, 20, 1145-1147.	1.4	38
35	Multiple sclerosis in the Iranian immigrant population of BC, Canada: prevalence and risk factors. Multiple Sclerosis Journal, 2014, 20, 1182-1188.	1.4	24
36	Prevalence of primary outcome changes in clinical trials registered on ClinicalTrials.gov: a cross-sectional study. F1000Research, 2014, 3, 77.	0.8	40

SREERAM V RAMAGOPALAN

#	Article	IF	CITATIONS
37	Using Twitter to investigate opinions about multiple sclerosis treatments: a descriptive, exploratory study. F1000Research, 2014, 3, 216.	0.8	21
38	Associations between selected immune-mediated diseases and tuberculosis: record-linkage studies. BMC Medicine, 2013, 11, 97.	2.3	49
39	Association of smoking with risk of multiple sclerosis: a population-based study. Journal of Neurology, 2013, 260, 1778-1781.	1.8	39
40	The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Multiple Sclerosis Journal, 2013, 19, 1571-1579.	1.4	84
41	Hospital admissions for vitamin D related conditions and subsequent immune-mediated disease: record-linkage studies. BMC Medicine, 2013, 11, 171.	2.3	31
42	Sex ratio of infectious mononucleosis and possible relevance to multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 359-361.	1.4	9
43	Buccals are likely to be a more informative surrogate tissue than blood for epigenome-wide association studies. Epigenetics, 2013, 8, 445-454.	1.3	140
44	The promise and challenges of blood spot methylomics. Epigenetics, 2013, 8, 775-777.	1.3	10
45	Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 793-795.	0.9	64
46	Concealed effects of gene–environment interactions in genome-wide association. Multiple Sclerosis and Related Disorders, 2012, 1, 39-42.	0.9	3
47	Early life child exposure and the risk of multiple sclerosis: A population based study. Journal of the Neurological Sciences, 2011, 307, 162-163.	0.3	3
48	Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Medicine, 2011, 9, 1.	2.3	440
49	Rare variants in the <i>CYP27B1</i> gene are associated with multiple sclerosis. Annals of Neurology, 2011, 70, 881-886.	2.8	204
50	Role of the HLA System in the Association Between Multiple Sclerosis and Infectious Mononucleosis. Archives of Neurology, 2011, 68, 469.	4.9	17
51	What is Next for the Genetics of Multiple Sclerosis?. Autoimmune Diseases, 2011, 2011, 1-3.	2.7	5
52	Geography of hospital admissions for multiple sclerosis in England and comparison with the geography of hospital admissions for infectious mononucleosis: a descriptive study. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 682-687.	0.9	19
53	Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurology, The, 2010, 9, 727-739.	4.9	459
54	Congenital Abnormalities and Multiple Sclerosis. BMC Neurology, 2010, 10, 115.	0.8	11

4

SREERAM V RAMAGOPALAN

#	Article	IF	CITATIONS
55	A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution. Genome Research, 2010, 20, 1352-1360.	2.4	737
56	Environmental factors and their timing in adult-onset multiple sclerosis. Nature Reviews Neurology, 2010, 6, 156-166.	4.9	228
57	No Effect of Parental Age on Risk of Multiple Sclerosis: A Population-Based Study. Neuroepidemiology, 2010, 34, 106-109.	1.1	10
58	Childhood cow's milk allergy and the risk of multiple sclerosis: A population based study. Journal of the Neurological Sciences, 2010, 291, 86-88.	0.3	8
59	Association of Infectious Mononucleosis with Multiple Sclerosis. Neuroepidemiology, 2009, 32, 257-262.	1.1	85
60	Parent-of-origin of HLA-DRB1*1501 and age of onset of multiple sclerosis. Journal of Human Genetics, 2009, 54, 547-549.	1.1	19
61	Expression of the Multiple Sclerosis-Associated MHC Class II Allele HLA-DRB1*1501 Is Regulated by Vitamin D. PLoS Genetics, 2009, 5, e1000369.	1.5	442
62	Variants in ST8SIA1 do not play a major role in susceptibility to multiple sclerosis in Canadian families. Journal of Neuroimmunology, 2009, 212, 142-144.	1.1	1
63	Multiple sclerosis: major histocompatibility complexity and antigen presentation. Genome Medicine, 2009, 1, 105.	3.6	48
64	Multiple sclerosis and the major histocompatibility complex. Current Opinion in Neurology, 2009, 22, 219-225.	1.8	77
65	Parental transmission of HLA-DRB1*15 in multiple sclerosis. Human Genetics, 2008, 122, 661-663.	1.8	47
66	Methylation of class II transactivator gene promoter IV is not associated with susceptibility to Multiple Sclerosis. BMC Medical Genetics, 2008, 9, 63.	2.1	18
67	No effect of preterm birth on the risk of multiple sclerosis: a population based study. BMC Neurology, 2008, 8, 30.	0.8	12
68	The genetics of clinical outcome in multiple sclerosis. Journal of Neuroimmunology, 2008, 201-202, 183-199.	1.1	49
69	Parental non-inherited HLA resistance alleles do not confer protection against multiple sclerosis. Journal of Neuroimmunology, 2008, 196, 170-172.	1.1	3
70	Genes for multiple sclerosis. Lancet, The, 2008, 371, 283-285.	6.3	41
71	No Effect of Birth Weight on the Risk of Multiple Sclerosis. Neuroepidemiology, 2008, 31, 181-184.	1.1	13
72	The Inheritance of Resistance Alleles in Multiple Sclerosis. PLoS Genetics, 2007, 3, e150.	1.5	109

#	Article	IF	CITATIONS
73	Origins of magic: review of genetic and epigenetic effects. BMJ: British Medical Journal, 2007, 335, 1299-1301.	2.4	4
74	A genome-wide scan in forty large pedigrees with multiple sclerosis. Journal of Human Genetics, 2007, 52, 955-962.	1.1	30
75	Suppressor Alleles in Multiple Sclerosis: Inheritance and Interactions. PLoS Genetics, 2005, preprint, e150.	1.5	Ο